Calendario de promoción Kazia Therapeutics Limited
Horario avanzado
gráfico sencillo
Acerca de la empresa Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.| IPO date | 1999-01-06 |
|---|---|
| ISIN | US48669G1058 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | aud |
| Див.доход ао | 53.19 |
| Дивиденд ао | 4.09 |
| Сайт | https://www.kaziatherapeutics.com |
| Цена ао | 0.96 |
| Cambio de precio por día: | 0% (0.9952) |
|---|---|
| Cambio de precio por semana.: | +4.79% (0.9497) |
| Cambio de precio por mes: | +5.91% (0.9397) |
| Cambio de precio en 3 meses.: | -70.11% (3.33) |
| Cambio de precio en seis meses: | +192.71% (0.34) |
| Cambio de precio por año: | +290.43% (0.2549) |
| Cambio de precio en 3 años.: | -83.55% (6.05) |
| Cambio de precio en 5 años.: | -75.27% (4.0238) |
| Cambio de precio desde principios de año.: | -67.05% (3.02) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Armistice Capital, LLC | 2475555 | 10.47 |
| Platinum Investment Management Ltd | 1821887 | 7.71 |
| Morgan Stanley | 201550 | 0.85 |
| Bank of Montreal/Can/ | 140166 | 0.59 |
| HSBC Holdings PLC | 100194 | 0.42 |
| TWO SIGMA SECURITIES, LLC | 58423 | 0.25 |
| XTX Topco Ltd | 19436 | 0.08 |
| Acadian Asset Management. LLC | 18682 | 0.08 |
| Citadel Advisors Llc | 12809 | 0.05 |
| BNP Paribas Financial Markets | 12700 | 0.05 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Ms. Anna Sandham | Company Secretary | N/A | |
| Dr. John Edwin Friend II, M.D. | CEO, MD & Director | 731.09k | 1970 (55 años) |
| Ms. Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer | 178.56k |
DIRECCIÓN: Australia, Sydney, Three International Towers - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.kaziatherapeutics.com
Sitio web: https://www.kaziatherapeutics.com
